🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06109337
Recruiting Observational

Immunoprofilling of Peripheral Blood Mononuclear Cells in Children With Attention Deficit/Hyperactivity Disorder

NCT06109337 · tracked via the Priya Life Science China tracker
Sponsor
First Affiliated Hospital of Zhejiang University
Phase
Observational
Started
2023-12-04
Last updated
2025-04-01

Condition(s) studied

ADHDImmune SystemClinical Syndrome

Investigational drug(s) / intervention(s)

drow blood

drow blood: Participants will be taken peripheral blood about 5 ml

Study summary

The goal of this observational study is to learn about The immune cell landscape of peripheral blood mononuclear cells in children with ADHD compared to typically developing controls. The main question it aims to answer are: 1.Testing the differences in immune cell subpopulations, protein expression and signaling pathways and cell subsets between two groups 2. Exploring the correlations between immune function in PBMC and resting-state brain functional networks in children with ADHD.

Participants will be taken peripheral blood about 5 ml , cognitive assessment including Intelligence testing, Stroop color-word test and Trail making test, clinical interview and brain structural and functional MRI.

Eligibility

Sex
ALL
Min age
6 Years
Max age
12 Years
Healthy volunteers
Accepted
Inclusion Criteria: Clinical diagnosis of ADHD; Children with an IQ≥70; Both parents are Han; Agree to take venous blood with informed consent; Exclusion Criteria: Schizophrenia, mood disorder, autism, mental retardation; Obvious physical and nervous system abnormalities;

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Fu Guanghui Hangzhou Zhejiang Recruiting

More First Affiliated Hospital of Zhejiang University trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06109337 on ClinicalTrials.gov ↗ ← All trials in China